Medical Marijuana, Inc. Portfolio Company KannaLife Sciences Covered by International Press for Signing New License With NIH to Develop Treatment for CTE Using Medicinal Marijuana

SAN DIEGO, Aug 20, 2014 (GLOBE NEWSWIRE via COMTEX) From the US to Turkey, the world is buzzing with the news that the National Institutes of Health, a U.S. Government Agency division of the Department of Health and Human Services, has approved KannaLife s drug discovery plan for using cannabis as the source for a new drug that will treat a concussion syndrome called Chronic Traumatic Encephalopathy or CTE. Medical Marijuana, Inc. (OTC Pink: MJNA) is proud to announce that one of its investment portfolio companies, KannaLife Sciences, Inc. ( KannaLife ), is the subject of this tremendous amount of mainstream news coverage. MJNA directly owns 16.70% of KannaLife s capital stock. KannaLife co-founder Thoma Kikis stated in a recent interview, On the FDA drug pipeline, we are focused on treating diseases that affect the brain. Kikis went on to explain that CTE is a concussion-induced disease with long-term effects mostly suffered by football, hockey, soccer players and boxers. CTE is def
http://bit.ly/1uWHxoU